Evidence mapPaperPMID 39778518Full record

ArticleCell metabolism2025

Advancing de novo lipogenesis: Genetic and metabolic insights.

Sean M Hartig, Mark A Herman

Abstract read
In one paragraph

Article in Cell metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sean M HartigSection of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Mark A HermanSection of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Electronic address: mark.herman@bcm.edu.

Funding

MICRORNA REGULATION OF ADIPOSE TISSUE IMMUNE RESPONSE IN OBESITYR01DK139397 · BAYLOR COLLEGE OF MEDICINE · 2025 to 2025
$669k
Molecular regulation of leptin bioavailabilityR01DK138018 · BAYLOR COLLEGE OF MEDICINE · 2025 to 2025
$643k
Metabolic Impacts of Type II Interferon Signals in ObesityR01DK114356 · BAYLOR COLLEGE OF MEDICINE · 2025 to 2025
$498k
NIDDK NIH HHS R01 DK100425NIDDK NIH HHS R01 DK114356NIDDK NIH HHS R01 DK121710NIDDK NIH HHS R01 DK138018NIDDK NIH HHS R01 DK139397
6 · The paper itself

Abstract

De novo lipogenesis (DNL) is the process whereby cells synthesize fatty acids from acetyl-CoA, contributing to steatosis in fatty liver disease. Two new studies, using genetic mouse models, metabolomics, and pharmacology, identified alternative pathways in DNL and unexpected physiological effects when targeting key enzymes in this pathway.

Indexed as

LipogenesisAcetyl Coenzyme AAnimalsFatty AcidsFatty LiverHumansMiceAcetyl Coenzyme AFatty Acids

Identifiers

PMID39778518
PMCPMC13050314

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.